MELBOURNE, Fla., April 5, 2011 /PRNewswire/ — Medicomp Inc.,
previously a wholly-owned subsidiary of United Therapeutics
Corporation, announced today that it has been acquired by an
investment group made up of current and past Medicomp management
led by Dan Balda, MD, Medicomp’s President and CEO. The sale
was finalized on March 31, 2011 and will allow the new Medicomp
organization to focus on growing the Medicomp brand and business to
become the medical monitoring center to the world. United
Therapeutics retained a minority stake in the company as part of
the sale.
(Logo:
https://photos.prnewswire.com/prnh/20100511/FL02219LOGO)
“We are extremely excited about this opportunity to grow
Medicomp and better assist physicians in diagnosing and treating
cardiac disease. Our independence will enable increased focus so we
can quickly add new technology partners, further increase the value
we bring to patients, maximize clinically significant results to
physicians, and seamlessly integrate into the medical community
while injecting cost effectiveness into the healthcare system,”
stated Dr. Balda.
Medicomp will maintain and grow the current management structure
to ensure that Medicomp customers are not impacted in any way by
this change.
About Medicomp Inc.
Medicomp Inc (www.medicompinc.com),
develops and provides advanced cardiac monitoring products and
services using the most sophisticated and reliable ambulatory
heart-monitoring systems available. Medicomp’s diagnostic
technologies are widely regarded as the most advanced in the
industry, and they are therefore entrusted by physicians and
scientists to provide cardiac monitoring services around the world
in healthcare, research as well as space and aeronautical
exploration.
Medicomp’s cardiac monitors use artificial intelligence
operating in real-time. Our proprietary Diogenes algorithm employs
rate, rhythm, morphol
‘/>”/>
